Targeting Peroxisome Proliferator Activated Receptor α (PPAR α) for the Prevention of Mitochondrial Impairment and Hypertrophy in Cardiomyocytes
Background/Aims: Morphological and biochemical maladaptation of cardiomyocytes are associated with mitochondrial dysfunction and dysregulation in hypertrophic conditions. Peroxisome proliferator activated receptor α (PPARα), a drug target for dyslipidemia, is known to be downregulated in cardiomyocy...
Main Authors: | Dipak Kar, Arun Bandyopadhyay |
---|---|
Format: | Article |
Language: | English |
Published: |
Cell Physiol Biochem Press GmbH & Co KG
2018-08-01
|
Series: | Cellular Physiology and Biochemistry |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/492875 |
Similar Items
-
Pleiotropic effects of PPAR-α – from benchside to bedside
by: I. V. Shirinsky, et al.
Published: (2021-06-01) -
EETs/PPARs activation together mediates the preventive effect of naringenin in high glucose-induced cardiomyocyte hypertrophy
by: Jie Zhang, et al.
Published: (2019-01-01) -
FABP3 Deficiency Exacerbates Metabolic Derangement in Cardiac Hypertrophy and Heart Failure via PPARα Pathway
by: Lingfang Zhuang, et al.
Published: (2021-08-01) -
The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
by: Montserrat A. de la Rosa Rodriguez, et al.
Published: (2018-06-01) -
Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy
by: Jing Yu, et al.
Published: (2021-09-01)